Atlas of Imaging in Cardio-Oncology

Richard M. SteingartWith more than 25 years of experience as a clinician, researcher, and educator in cardiovascular diseases, Dr Steingart joined Memorial Sloan Kettering as Chief of the Cardiology Service in 2003. MSK’s Cardiology Service is one of the world’s leading programs devoted exclusively to the management of cardiovascular diseases in cancer patients. The many facets of this program share a common goal: to facilitate the delivery of optimal cancer therapy in patients who are at risk for or who have existing heart disease. Careful communication with other members of the MSK treatment team — including oncologists, surgeons, radiologists, radiation therapists, and medical subspecialists — makes this possible. On a practical level, this effort reduces the risk of cancer patients developing heart disease, and allows more patients who have both cancer and heart disease to safely receive the optimal therapy for their cancer.Jennifer E. LiuDr. Liu is the Director of the Cardiovascular Laboratories at Memorial Sloan Kettering Cancer Center. She has more than 20 years of experience in echocardiography and is a recognized leader in the field of cardiovascular imaging in Cardio Oncology. As an author of key expert consensus documents, she is dedicated to setting the standard of practice on the contemporary use of echocardiography in the management of patients during and after cancer therapy. Her clinical and research interests include the development of imaging-based strategies for early diagnosis and management of cardiotoxicity to optimize cardiovascular health in patients with cancer.    She is the founder of the annual MSK Cardio Oncology symposium which provides a case-based curriculum to educate clinicians involved in the care of cancer patients.

• Multimodality Imaging in Cardio-Oncology.- Anthracycline/Trastuzumab Cardiac Toxicity.- Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis.- Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy.- Introduction to Tyrosine Kinase Inhibitors: Pazopanib Cardiotoxicity.- Tyrosine Kinase Inhibitors: Arrhythmias and Coagulopathy.- Vascular Toxicity of Tyrosine Kinase Inhibitors: Peripheral Vascular and Coronary Artery Disease.- Vascular Toxicity of Tyrosine Kinase Inhibitors: Coronary Artery Disease.- Vascular Toxicity of Tyrosine Kinase Inhibitors: Pulmonary Hypertension.- Cardiovascular Toxicities of Proteasome Inhibitors.- Cardiac Complications of 5-Flourouracil (5FU) and Capecitabine Therapy.- Cisplatin and Carboplatin.- Cardiac Risk Assessment Prior to Hematopoietic Stem Cell Transplantation: Cases and Management Strategies.- The Role of Myocardial Perfusion Imaging in Cardiac Clearance of Cancer Patients.- Perioperative Management of the Cancer Patient.- Masses Involving the Heart and Vasculature.- Carcinoid Heart Disease.- Cardiac Amyloidosis.- Stress-induced Cardiomyopathy.- Arterial Thrombosis:  Marantic Endocarditis.- Pericardial Effusion, Tamponade, and Constrictive Pericarditis.- Introduction to the Cardiac Implications of Radiotherapy.- Cardio-Oncologists’ Perspective on the Cardiac Implications of Radiotherapy: Complex Cases of Radiation-related Valvular and Vascular Disease.- Radiation-related Coronary and Conduction System Disease.- Radiation Injury to the Heart, Great Vessels, and Their Branches.- Cardiac Constriction and Restriction After Chest Radiotherapy for Hodgkin’s Lymphoma and Breast Cancer.- Onset of Heart Failure After Anthracycline Therapy in the Adult: Treatment and Expectations for Recovery.- Heart Failure in Long-term Survivors of Childhood or Adolescent Cancers.- Health Care Disparities in Cardio-Oncology.- Cardio-Oncology Practice in the Community.- Cardio-Oncology in the COVID-19 Era.- Acute Cardiac Care ofCancer Patients.